Ethics committee

What it is

An ethics committee is an independent body that reviews human research before it starts and monitors it to protect participants. In India, every clinical trial site must have ethics review, and Indian regulations require an ethics committee for biomedical and health research to include at least 7 members with varied expertise and lay representation.

You may also see the terms institutional ethics committee (IEC), independent ethics committee, or research ethics committee. In many international documents, a similar body is called an institutional review board (IRB). The core job is the same: to make sure a study involving people is ethically acceptable, that risks are reasonable, that consent is proper, and that participants' rights, safety, and well-being come first.

For patients considering a cancer clinical trial, the ethics committee is one of the main safeguards outside the treating team and sponsor. It does not "run" the study. Instead, it independently reviews the protocol, patient information sheet, consent form, recruitment materials, compensation plans, privacy protections, and safety reporting arrangements.

A typical ethics committee includes scientific and non-scientific members so that decisions are not made only by researchers. Under Indian Council of Medical Research (ICMR) guidance, membership commonly includes a chairperson, member secretary, clinicians, basic medical scientists, legal expert, social scientist or NGO representative, ethicist or philosopher, and lay person or community representative.

Term	Usual meaning
Institutional ethics committee (IEC)	Ethics committee based at a hospital, medical college, or research institution
Independent ethics committee	A committee intended to review research independently of investigators and sponsors
Research ethics committee	Broad term used in many countries for a body reviewing human research
Institutional review board (IRB)	Common U.S. term for a research ethics committee

How it works

Ethics committees review a study before approval, and many also continue oversight while the study is running. Their review is based on established ethics principles such as respect for persons, beneficence, and justice, along with national regulations and Good Clinical Practice standards.

In practical terms, the committee asks questions such as:

1. Is the research question important and scientifically sound?
2. Are the risks minimised as far as possible?
3. Are the potential benefits and burdens fairly distributed?
4. Is informed consent clear, complete, and understandable?
5. Are privacy and confidentiality protected?
6. Is there a plan to report serious adverse events and protocol deviations?
7. Are vulnerable participants, such as children or very ill patients, given extra protection?

The committee may approve the study, ask for changes, defer a decision until more information is provided, or reject the proposal. Approval is usually not permanent. Ongoing review may include annual status reports, review of amendments, review of serious adverse events, and action if participant safety concerns arise.

For cancer trials, ethics committees often pay close attention to whether patients may feel pressured because standard options are limited, whether the consent form explains randomisation and side effects clearly, and whether compensation and medical management for trial-related injury are addressed.

Evidence and uses

Ethics committees are a standard part of modern human-subject research oversight worldwide. International Good Clinical Practice guidance describes the IRB/IEC as responsible for safeguarding the rights, safety, and well-being of trial subjects. Reviews in the medical literature describe ethics committees as an independent check on investigator bias, conflicts of interest, and overly risky or poorly explained studies.

Their main uses include review of:

• Clinical trials of drugs, devices, and procedures
• Observational studies involving patient data or samples
• Biobanking and genetic research
• Student and academic research involving human participants
• Amendments to ongoing studies
• Safety reports and protocol deviations

In India, the ICMR's National Ethical Guidelines for Biomedical and Health Research Involving Human Participants set out how ethics committees should be constituted and how they should function. For clinical trials, ethics review works alongside regulatory review by the Central Drugs Standard Control Organisation (CDSCO) when applicable. These are related but different processes: regulatory approval does not replace ethics approval.

Evidence on ethics committee performance is mixed. Research supports their importance as a participant-protection mechanism, but published analyses also note challenges such as variable quality of review, delays, inconsistent decisions between committees, administrative burden, and the need for training and accreditation. So the value of ethics committees is well established, but how consistently they perform across institutions can vary.

When to see a clinician

Patients and families usually do not "see" an ethics committee directly, but you should ask your doctor or trial coordinator about ethics approval if you are invited into a study. Reasonable questions include:

• Has this study been approved by an ethics committee at this site?
• Can I read the patient information sheet and consent form in my preferred language?
• Who pays for treatment if I am harmed by the study?
• Can I leave the study later without affecting my regular care?
• Who can I contact if I have a complaint or safety concern?

You should speak to your treating clinician, research nurse, or study coordinator if anything in the consent form is unclear, if you feel pressured to join, or if new side effects appear after enrollment. Many consent forms also list contact details for the ethics committee or an institutional office for participant complaints.

Limitations and open questions

Ethics committees are an important safeguard, but they are not a guarantee that a study is risk-free or that every problem will be prevented. They review the information available at the time and depend on investigators and sponsors to report amendments, deviations, and safety events accurately and on time.

Several open issues are discussed in the literature. One is how to make review more consistent across sites without losing local context. Another is how to review complex areas such as genomics, artificial intelligence, big-data research, and international data sharing. Committees also face practical limits, including workload, uneven training, and possible conflicts of interest if they are based within the same institution conducting the research.

For patients, the key point is simple: ethics committee approval is necessary, but it should be seen as one layer of protection, not the only one. Your own understanding of the study, the quality of the consent discussion, the experience of the research team, and ongoing safety monitoring all matter.